Amended Statement of Ownership (sc 13g/a)
February 08 2021 - 06:07AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
WASHINGTON, DC
20549
SCHEDULE 13G
Under the Securities Exchange Act
of 1934
(Amendment No. 4)
ZYNERBA PHARMACEUTICALS,
INC.
(Name of Issuer)
Common Stock, $0.001 par
value
(Title of Class of
Securities)
98986X109
(CUSIP Number)
December 31, 2020
(Date of Event Which Requires Filing
of this Statement)
Check the appropriate box to
designate the rule pursuant to which this Schedule is
filed:
*The remainder of this cover
page shall be filled out for a reporting person’s initial
filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information
which would alter the disclosures provided in a prior cover
page.
The information required in the
remainder of this cover page shall not be deemed to be “filed”
for purposes of Section 18 of the Securities Exchange Act of
1934 (“Act”) or otherwise subject to the liabilities of that
section of the Act but shall be subject to all other provisions of
the Act (however, see the Notes).
CUSIP No: 98986X109
| |
(1) |
Names of Reporting
Persons |
| |
|
Michael
Rapoport |
| |
|
|
| |
(2) |
Check the Appropriate Box
if a Member of a Group (See Instructions) |
| |
|
|
| |
|
(a) |
¨ |
| |
|
|
|
| |
|
(b) |
¨ |
| |
|
|
| |
(3) |
SEC Use Only |
| |
|
|
| |
(4) |
Citizenship or Place of Organization |
| |
|
United States of
America |
| |
|
|
| |
|
Number of Shares Beneficially Owned by Each
Reporting Person With |
| |
|
|
| |
|
(5) |
Sole
Voting Power |
| |
|
|
0 |
| |
|
|
|
| |
|
(6) |
Shared
Voting Power |
| |
|
|
0 |
| |
|
|
|
| |
|
(7) |
Sole
Dispositive Power |
| |
|
|
0 |
| |
|
|
|
| |
|
(8) |
Shared
Dispositive Power |
| |
|
|
0 |
| |
|
|
|
| |
(9) |
Aggregate Amount Beneficially Owned by Each
Reporting Person |
| |
|
0 shares of
Common Stock |
| |
|
|
| |
(10) |
Check Box if the Aggregate Amount in Row (9)
Excludes Certain Shares (See Instructions) ¨ |
| |
|
|
| |
(11) |
Percent of Class Represented by Amount in Row
(9) |
| |
|
0% |
| |
|
|
| |
(12) |
Type of Reporting Person (See
Instructions) |
| |
|
IN |
SCHEDULE 13G
CUSIP
No: 98986X109
Item 1.
|
(a) |
Name of Issuer
Zynerba Pharmaceuticals, Inc. (the “Issuer”) |
|
(b) |
Address of Issuer’s Principal
Executive Offices
80 W. Lancaster Avenue, Suite 300, Devon, PA 19333 |
| Item 2 (a). |
Name of
Person Filing |
| |
|
| |
Michael Rapoport |
| Item 2 (b). |
Address
of Principal Business Office or, if none,
Residence |
| |
|
| |
105 S. Narcissus Avenue, Suite 705,
West Palm Beach, FL 33401 |
| Item 2 (c). |
Citizenship |
| |
|
| |
This
Schedule 13G is being filed on behalf of Michael Rapoport, an
individual who is a citizen of the United States of
America. |
| |
|
| |
The
principal business office of Michael Rapoport is 105 S. Narcissus
Avenue, Suite 705, West Palm Beach, FL 33401. |
| |
|
| Item 2
(d) |
Title of Class of Securities |
| |
Common
Stock, par value $0.001 per share |
| |
|
| Item 2 (e) |
CUSIP Number |
| |
98986X109 |
| Item 3. |
If
this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b)
or (c), check whether the person filing is a: |
Not applicable.
Provide the following information
regarding the aggregate number and percentage of the class of
securities of the issuer identified in Item 1.
|
(a) |
Amount Beneficially Owned: |
Michael Rapoport – 0 shares of Common
Stock
Michael Rapoport – 0%
|
(c) |
Number of shares as to which such person
has: |
|
(i) |
sole
power to vote or to direct the vote |
Michael Rapoport – 0 shares of Common
Stock
|
(ii) |
shared power to vote or to direct the
vote |
Michael Rapoport – 0
shares
|
(iii) |
sole
power to dispose or to direct the disposition of |
Michael Rapoport – 0 shares of Common
Stock
|
(iv) |
shared power to dispose or to direct the
disposition of |
Michael Rapoport – 0
shares
** The beneficial ownership
percentages herein are based on 29,439,175 shares of Common Stock
issued and outstanding as of November 5, 2020, as disclosed in the
Company’s Quarterly Report on Form 10-Q filed with the Securities
and Exchange Commission on November 9, 2020.
| Item 5. |
Ownership of Five Percent or Less of a
Class |
If this statement is being filed to
report the fact that as of the date hereof the reporting person has
ceased to be the beneficial owner of more than five percent of the
class of securities, check the following: x
| Item 6. |
Ownership of More than Five Percent on Behalf
of Another Person |
Not applicable.
| Item 7. |
Identification and Classification of the
Subsidiary Which Acquired the Security Being Reported on By the
Parent Holding Company or Control Person |
Not applicable.
| Item 8. |
Identification and Classification of Members
of the Group |
Not applicable.
| Item 9. |
Notice
of Dissolution of Group |
Not applicable.
By signing below each of the
undersigned certifies that, to the best of its knowledge and
belief, the securities referred to above were not acquired and are
not held for the purpose of or with the effect of changing or
influencing the control of the issuer of the securities and were
not acquired and are not held in connection with or as a
participant in any transaction having that purpose or
effect.
SIGNATURES
After reasonable inquiry and to the
best of my knowledge and belief, I certify that the information set
forth in this statement is true, complete and correct.
Date: February 5, 2021
|
|
/s/ Michael Rapoport |
| |
Michael
Rapoport |
